JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners

Discussions with companies during last month's 34th Annual J.P. Morgan Healthcare Conference in San Francisco revealed that immuno-oncology remains as hot as ever with developers of targeted therapeutics shifting their focus to immunotherapies or agents that can be combined with the immune system-harnessing treatments for cancer.